BLRX
BioLineRx Ltd.
$3.25
-$0.13(-3.85%)
36
Overall
--
Value
36
Tech
--
Quality
Market Cap
$11.94M
Volume
19.17K
52W Range
$2.30 - $14.80
Target Price
$26.00
Company Overview
| Mkt Cap | $11.94M | Price | $3.25 |
| Volume | 19.17K | Change | -3.85% |
| P/E Ratio | -1.3 | Open | $3.20 |
| Revenue | $22.9M | Prev Close | $3.38 |
| Net Income | $-9.2M | 52W Range | $2.30 - $14.80 |
| Div Yield | N/A | Target | $26.00 |
| Overall | 36 | Value | -- |
| Quality | -- | Technical | 36 |
No chart data available
About BioLineRx Ltd.
BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It also develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.
Sector: Healthcare
Industry: Biotechnology
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | BLRX | $3.25 | -3.8% | 19.17K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |